Education
About Us
Working with TipRanks
Follow Us
Cellectar Biosciences (CLRB)
NASDAQ:CLRB
Total Valuation
Cellectar Biosciences has a market cap or net worth of $17.62M. The enterprise value is $2.75M.
Market Cap$17.62M
Enterprise Value$2.75M
Share Statistics
Cellectar Biosciences has 3,192,040 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding3,192,040
Owned by Insiders31.96%
Owned by Institutions0.33%
Financial Efficiency
Cellectar Biosciences’s return on equity (ROE) is -3.12 and return on invested capital (ROIC) is -320.67%.
Return on Equity (ROE)-3.12
Return on Assets (ROA)-1.75
Return on Invested Capital (ROIC)-320.67%
Return on Capital Employed (ROCE)-3.22
Revenue Per Employee0.00
Profits Per Employee-4.05M
Employee Count11
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Cellectar Biosciences is ―. Cellectar Biosciences’s PEG ratio is ―.
PE Ratio―
PS Ratio―
PB Ratio―
Price to Fair Value0.96
Price to FCF―
Price to Operating Cash Flow-0.23
PEG Ratio―
Income Statement
In the last 12 months, Cellectar Biosciences had revenue of 0.00 and earned -44.58M in profits. Earnings per share was -40.72.
Revenue0.00
Gross Profit0.00
Operating Income-51.78M
Pretax Income-44.52M
Net Income-44.58M
EBITDA-51.49M
Earnings Per Share (EPS)-40.72
Cash Flow
In the last 12 months, operating cash flow was -34.58M and capital expenditures -61.29K, giving a free cash flow of -34.64M billion.
Operating Cash Flow-34.58M
Free Cash Flow-34.64M
Free Cash Flow per Share-10.85
Dividends & Yields
Cellectar Biosciences pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.41
52-Week Price Change-90.98%
50-Day Moving Average4.96
200-Day Moving Average7.92
Relative Strength Index (RSI)55.65
Average Volume (3m)136.15K
Important Dates
Cellectar Biosciences upcoming earnings date is Oct 30, 2025, TBA (Confirmed).
Last Earnings DateAug 14, 2025
Next Earnings DateOct 30, 2025
Ex-Dividend Date―
Financial Position
Cellectar Biosciences as a current ratio of 2.58, with Debt / Equity ratio of 6.07%
Current Ratio2.58
Quick Ratio2.58
Debt to Market Cap0.00
Net Debt to EBITDA0.44
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Cellectar Biosciences has paid 66.00K in taxes.
Income Tax66.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Cellectar Biosciences EV to EBITDA ratio is 0.18, with an EV/FCF ratio of 0.19.
EV to Sales0.00
EV to EBITDA0.18
EV to Free Cash Flow0.19
EV to Operating Cash Flow0.19
Balance Sheet
Cellectar Biosciences has $11.04M in cash and marketable securities with $453.51K in debt, giving a net cash position of $10.59M billion.
Cash & Marketable Securities$11.04M
Total Debt$453.51K
Net Cash$10.59M
Net Cash Per Share$3.32
Tangible Book Value Per Share$9.31
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Cellectar Biosciences is $15.20, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$15.20
Price Target Upside175.36% Upside
Analyst ConsensusModerate Buy
Analyst Count3
Revenue Growth Forecast―
EPS Growth Forecast73.37%